天康生物
(002100)
| 流通市值：85.60亿 | | | 总市值：85.60亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,180,253,944.24 | 17,175,805,190.11 | 13,087,153,128.58 | 7,993,043,517.91 |
| 营业收入 | 4,180,253,944.24 | 17,175,805,190.11 | 13,087,153,128.58 | 7,993,043,517.91 |
| 二、营业总成本 | 4,012,088,136.8 | 16,479,483,378.21 | 12,617,293,868.82 | 7,789,522,484.27 |
| 营业成本 | 3,685,986,705.54 | 15,090,298,865.63 | 11,518,612,004.77 | 7,074,450,248.55 |
| 税金及附加 | 12,155,303.45 | 47,054,072.14 | 33,021,523.2 | 21,706,298.76 |
| 销售费用 | 105,364,201.59 | 427,635,411.73 | 353,352,827.23 | 233,330,190.16 |
| 管理费用 | 121,200,724.44 | 559,620,695.66 | 345,479,562.81 | 223,811,636.83 |
| 研发费用 | 50,150,345.89 | 200,252,390.3 | 249,626,186.54 | 154,290,133.74 |
| 财务费用 | 37,230,855.89 | 154,621,942.75 | 117,201,764.27 | 81,933,976.23 |
| 其中:利息费用 | 39,756,510.02 | 178,940,936.76 | 137,878,753.27 | 95,463,022.93 |
| 其中:利息收入 | -8,321,946.2 | 38,644,572.51 | 28,568,918.16 | 19,724,310.43 |
| 加:公允价值变动收益 | -26,478.3 | 50,872.22 | 72,374.02 | 48,766.16 |
| 加:投资收益 | -7,557,835.32 | -1,917,176.15 | -213,767.38 | -1,149,498.28 |
| 资产处置收益 | -1,641,062.85 | 4,500,658.4 | 2,266,143.89 | 878,022.72 |
| 资产减值损失(新) | -536,573.35 | -22,737,961.15 | 95,718,626.13 | 96,341,988.33 |
| 信用减值损失(新) | -21,136,956.4 | -109,418,167.84 | -29,898,067.63 | -16,973,222.79 |
| 其他收益 | 17,449,920.54 | 64,309,885.27 | 49,596,015.55 | 34,676,656.18 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 154,716,821.76 | 631,109,922.65 | 587,400,584.34 | 317,343,745.96 |
| 加:营业外收入 | 25,508,794.1 | 30,113,385.71 | 18,700,553.23 | 694,084.89 |
| 减:营业外支出 | 7,692,039.35 | 50,410,872.72 | 34,113,120.11 | 24,240,518.8 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 172,533,576.51 | 610,812,435.64 | 571,988,017.46 | 293,797,312.05 |
| 减:所得税费用 | 1,092,034.48 | 14,391,247.6 | 17,492,247.88 | 14,031,521.47 |
| 六、净利润 | 171,441,542.03 | 596,421,188.04 | 554,495,769.58 | 279,765,790.58 |
| 持续经营净利润 | 171,441,542.03 | 596,421,188.04 | 554,495,769.58 | 279,765,790.58 |
| 归属于母公司股东的净利润 | 148,142,983.18 | 605,052,882.38 | 565,624,390.53 | 276,682,923.94 |
| 少数股东损益 | 23,298,558.85 | -8,631,694.34 | -11,128,620.95 | 3,082,866.64 |
| (一)基本每股收益 | 0.11 | 0.44 | 0.41 | 0.2 |
| (二)稀释每股收益 | 0.11 | 0.44 | 0.41 | 0.2 |
| 八、其他综合收益 | -41,188,202.22 | 225,776.62 | 3,086,398.37 | -40,712,722.89 |
| 归属于母公司股东的其他综合收益 | -41,212,253.56 | -57,921.96 | 3,877,421.26 | -40,833,921.2 |
| 九、综合收益总额 | 130,253,339.81 | 596,646,964.66 | 557,582,167.95 | 239,053,067.69 |
| 归属于母公司股东的综合收益总额 | 106,930,729.62 | 604,994,960.42 | 569,501,811.79 | 235,849,002.74 |
| 归属于少数股东的综合收益总额 | 23,322,610.19 | -8,347,995.76 | -11,919,643.84 | 3,204,064.95 |
| 公告日期 | 2025-04-30 | 2025-04-29 | 2024-10-29 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |